IMBALANCE OF IL -1β И IL -1RA CYTOKINES IN BLOOD SERUM AND BRONCHOALVEOLAR LAVAGE IN COPD PATIENTS
Abstract. The aim of present study was to determine levels of IL-1β and its inhibitor, IL-1ra in blood serum and bronchoalveolar lavage fluid (BALF) of 20 patients with COPD, depending on severity of their disease, activity of inflammatory process, bacterial and viral complication. Methods. Twenty m...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
SPb RAACI
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1c513bcbc1284ddea6691a12e3a98182 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Abstract. The aim of present study was to determine levels of IL-1β and its inhibitor, IL-1ra in blood serum and bronchoalveolar lavage fluid (BALF) of 20 patients with COPD, depending on severity of their disease, activity of inflammatory process, bacterial and viral complication. Methods. Twenty male patients with COPD (stage 2 to 4) were examined. It was shown that all the patients with COPD displayed high levels of IL-1β, both in the area of inflammation, and in blood serum. The latter index was dependent on the severity of disease and activity of inflammatory process. In BALF, the contents of IL-1β in all the patients under study was significantly exceeded the normal levels of this cytokine even at the earliest stages of evolving COPD. concentration in serum was depended at stage of disease and activity of inflammatory procces. There were no differences in IL-1β concentrations in BALF of 2 - 4 stage COPD patients. IL-1ra levels in the patients’ serum were within normal levels, and tended to increase in BAL, thus causing imbalanced IL-1ra/IL-1β ratio both in the inflammatory area, as well as systemically. The maximal detection of respiratory pathogens did significantly correlate with decreased IL-1ra/ IL-1β ratio, thus confirming the data on infectious agents as a pathogenetic component in COPD. |
|---|